期刊
MOLECULAR IMAGING AND BIOLOGY
卷 13, 期 3, 页码 547-557出版社
SPRINGER
DOI: 10.1007/s11307-010-0361-6
关键词
[18F]FLT PET; Glioma; Suicide gene therapy; HSV-1-tk
资金
- Deutsche Forschungsgemeinschaft [DFG-Ja98/1-2)]
- Center for Molecular Medicine Cologne [CMMC-TV46]
- EU [LSHC-CT-2004-503569]
The purpose of this study was to investigate the potential of 3'-deoxy-3'-[F-18]fluorothymidine ([F-18]FLT) positron emission tomography (PET) to detect early treatment responses in gliomas. Human glioma cells were stably transduced with genes yielding therapeutic activity, sorted for different levels of exogenous gene expression, and implanted subcutaneously into nude mice. Multimodality imaging during prodrug therapy included (a) magnetic resonance imaging, (b) PET with 9-(4-[F-18]fluoro-3-hydroxymethylbutyl)guanine assessing exogenous gene expression, and (c) repeat [F-18]FLT PET assessing antiproliferative therapeutic response. All stably transduced gliomas responded to therapy with significant reduction in tumor volume and [F-18]FLT accumulation within 3 days after initiation of therapy. The change in [F-18]FLT uptake before and after treatment correlated to volumetrically calculated growth rates. Therapeutic efficacy as monitored by [F-18]FLT PET correlated to levels of therapeutic gene expression measured in vivo. Thus, [F-18]FLT PET assesses early antiproliferative effects, making it a promising radiotracer for the development of novel treatments for glioma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据